Cargando…

Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics

Cancer is generally considered a result of genetic mutations that cause epigenetic changes, leading to anomalous cellular behavior. Since 1970s, an increasing understanding of the plasma membrane and specifically the lipid alterations in tumor cells have provided novel insights for cancer therapy. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Fei, Weidong, Yan, Jingjing, Wu, Xiaodong, Yang, Shan, Zhang, Xiao, Wang, Rong, Chen, Yue, Xu, Junjun, Zheng, Caihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196822/
https://www.ncbi.nlm.nih.gov/pubmed/37215569
http://dx.doi.org/10.7150/thno.82189
_version_ 1785044426737844224
author Fei, Weidong
Yan, Jingjing
Wu, Xiaodong
Yang, Shan
Zhang, Xiao
Wang, Rong
Chen, Yue
Xu, Junjun
Zheng, Caihong
author_facet Fei, Weidong
Yan, Jingjing
Wu, Xiaodong
Yang, Shan
Zhang, Xiao
Wang, Rong
Chen, Yue
Xu, Junjun
Zheng, Caihong
author_sort Fei, Weidong
collection PubMed
description Cancer is generally considered a result of genetic mutations that cause epigenetic changes, leading to anomalous cellular behavior. Since 1970s, an increasing understanding of the plasma membrane and specifically the lipid alterations in tumor cells have provided novel insights for cancer therapy. Moreover, the advances in nanotechnology offer a potential opportunity to target the tumor plasma membrane while minimizing side effects on normal cells. To further develop membrane lipid perturbing tumor therapy, the first section of this review demonstrates the association between plasma membrane physicochemical properties and tumor signaling, metastasis, and drug resistance. The second section highlights existing nanotherapeutic strategies for membrane disruption, including lipid peroxide accumulation, cholesterol regulation, membrane structure disruption, lipid raft immobilization, and energy-mediated plasma membrane perturbation. Finally, the third section evaluates the prospects and challenges of plasma membrane lipid perturbing therapy as a therapeutic strategy for cancers. The reviewed membrane lipid perturbing tumor therapy strategies are expected to bring about necessary changes in tumor therapy in the coming decades.
format Online
Article
Text
id pubmed-10196822
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-101968222023-05-20 Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics Fei, Weidong Yan, Jingjing Wu, Xiaodong Yang, Shan Zhang, Xiao Wang, Rong Chen, Yue Xu, Junjun Zheng, Caihong Theranostics Review Cancer is generally considered a result of genetic mutations that cause epigenetic changes, leading to anomalous cellular behavior. Since 1970s, an increasing understanding of the plasma membrane and specifically the lipid alterations in tumor cells have provided novel insights for cancer therapy. Moreover, the advances in nanotechnology offer a potential opportunity to target the tumor plasma membrane while minimizing side effects on normal cells. To further develop membrane lipid perturbing tumor therapy, the first section of this review demonstrates the association between plasma membrane physicochemical properties and tumor signaling, metastasis, and drug resistance. The second section highlights existing nanotherapeutic strategies for membrane disruption, including lipid peroxide accumulation, cholesterol regulation, membrane structure disruption, lipid raft immobilization, and energy-mediated plasma membrane perturbation. Finally, the third section evaluates the prospects and challenges of plasma membrane lipid perturbing therapy as a therapeutic strategy for cancers. The reviewed membrane lipid perturbing tumor therapy strategies are expected to bring about necessary changes in tumor therapy in the coming decades. Ivyspring International Publisher 2023-04-23 /pmc/articles/PMC10196822/ /pubmed/37215569 http://dx.doi.org/10.7150/thno.82189 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Fei, Weidong
Yan, Jingjing
Wu, Xiaodong
Yang, Shan
Zhang, Xiao
Wang, Rong
Chen, Yue
Xu, Junjun
Zheng, Caihong
Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics
title Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics
title_full Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics
title_fullStr Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics
title_full_unstemmed Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics
title_short Perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics
title_sort perturbing plasma membrane lipid: a new paradigm for tumor nanotherapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196822/
https://www.ncbi.nlm.nih.gov/pubmed/37215569
http://dx.doi.org/10.7150/thno.82189
work_keys_str_mv AT feiweidong perturbingplasmamembranelipidanewparadigmfortumornanotherapeutics
AT yanjingjing perturbingplasmamembranelipidanewparadigmfortumornanotherapeutics
AT wuxiaodong perturbingplasmamembranelipidanewparadigmfortumornanotherapeutics
AT yangshan perturbingplasmamembranelipidanewparadigmfortumornanotherapeutics
AT zhangxiao perturbingplasmamembranelipidanewparadigmfortumornanotherapeutics
AT wangrong perturbingplasmamembranelipidanewparadigmfortumornanotherapeutics
AT chenyue perturbingplasmamembranelipidanewparadigmfortumornanotherapeutics
AT xujunjun perturbingplasmamembranelipidanewparadigmfortumornanotherapeutics
AT zhengcaihong perturbingplasmamembranelipidanewparadigmfortumornanotherapeutics